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Despite respiratory syncytial virus (RSV) bronchiolitis remaining the
most common cause of lower respiratory tract disease in infants
worldwide, treatment has progressed little in the past 30 years. The
aim of our study was to determine whether post-infection admin-
istration of de novo pyrimidine synthesis inhibitors could prevent the
reduction in alveolar fluid clearance (AFC) and hypoxemia that
occurs at Day 2 after intranasal infection of BALB/c mice with RSV.
BALB/c mice were infected intranasally with RSV strain A2. AFC was
measured in anesthetized, ventilated mice after instillation of 5%
bovine serum albumin into the dependent lung. Post-infection sys-
temic treatment with leflunomide has no effect on AFC. However,
when added to the AFC instillate, leflunomide’s active metabolite,
A77-1726, blocks RSV-mediated inhibition of AFC at Day 2. This
block is reversed by uridine (which allows pyrimidine synthesis via
the scavenger pathway) and not recapitulated by genistein (which
mimics the tyrosine kinase inhibitor effects of A77-1726), indicating
that the effect is specific for the de novo pyrimidine synthesis path-
way. More importantly, when administered intranasally at Day 1,
A77-1726, but not its vehicle dimethyl sulfoxide, maintains its
beneficial effect on AFC and lung water content until Day 2. Intra-
nasal instillation of A77-1726 at Day 1 also reduces bronchoalveolar
lavage nucleotide levels, lung inflammation, and hypoxemia at
Day 2 without impairing viral replication at Day 2 or viral clearance
at Day 8. Post-infection intranasal or aerosolized treatment with
pyrimidine synthesis inhibitors may provide symptomatic relief
from the pathophysiologic sequelae of impaired AFC in children
with RSV bronchiolitis.
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Respiratory syncytial virus (RSV) remains the most common
cause of lower respiratory tract infection in infants and children
worldwide (1), and recent studies indicate that it has a disease
impact comparable to that of nonpandemic influenza A in the
elderly (2). However, while infant hospitalization rates for RSV
increased 2.4-fold from 1980 to 1996 (3), treatment for infants
with moderate to severe RSV bronchiolitis has progressed little
in the past 30 years: supplemental oxygen and periodic suction-
ing to remove excess nasopharyngeal secretions provide clear
benefit, but more specific pharmacologic therapies are moder-
ately successful at best (4). The need for new approaches to
RSV treatment is therefore paramount.
The interface between the respiratory epithelium and the air
is normally bathed by a thin layer of fluid, the airspace lining fluid
(ALF). To permit efficient gas exchange in the bronchoalveolar
compartment and effective mucociliary clearance in the airways,
the depth of this layer must be tightly regulated. Active transport
of sodium (Na1) ions from the ALF to the interstitial space by
bronchoalveolar epithelial cells is critical to the regulation of
ALF thickness (5). Inhibition of active Na1 transport can result
in formation of an excessive volume of ALF, impairment of gas
exchange (6), narrowing of airway lumens (7), and dilution of the
surface-active materials that stabilize small airways (8). The
resultant small airway obstruction, which would be exacerbated
by any intercurrent inflammatory process, such as that occurring
during RSV bronchiolitis, would be predicted to be most severe
in infancy and early childhood when airway diameter is lowest.
Moderately severe RSV bronchiolitis is commonly associ-
ated with signs of respiratory distress, and admission decisions
are often based upon clinical evidence of hypoxemia (4). The
underlying causes of hypoxemia in RSV bronchiolitis have not
been determined, but its presence must perforce indicate either
hypoventilation of the bronchoalveolar compartment (as a re-
sult perhaps of airway obstruction by fluid secretions, mucus,
inflammatory infiltrates, or necrotic cell debris), an abnormal
alveolar ventilation–perfusion ratio, and/or diminished respira-
tory membrane diffusion. Our previous findings suggest that
bronchoalveolar edema, occurring as a consequence of reduced
active Na1 transport by the respiratory epithelium, may be an
unrecognized component of RSV disease that plays a role in
development of hypoxemia, either by impairing alveolar gas
exchange or by contributing to obstruction of small airways (9).
We have found that infection of BALB/c mice with RSV
significantly impairs alveolar fluid clearance (AFC), an in vivo
measure of active Na1 transport in the whole lung, at early time
points after infection (by 43% from mock-infected values at
Day 2) (10). This decrease in AFC is mediated by de novo
synthesized UTP acting on P2Y purinergic receptors, and is
rapidly reversed by addition to the AFC instillate of agents that
degrade UTP, but not ATP (9, 10). Our studies also demon-
strated that RSV-mediated nucleotide release, AFC inhibition,
and physiologic sequelae thereof can be prevented by pretreat-
ment of mice with the de novo pyrimidine synthesis inhibitor
leflunomide (9). These findings suggested that inhibitors of
de novo pyrimidine synthesis, while not being antiviral, might
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be useful in alleviating symptoms of RSV bronchiolitis. How-
ever, as a consequence of its poor pharmacodynamic profile
(11), leflunomide is only effective in abrogating effects of RSV
on AFC when given as a systemic pretreatment regimen. This
renders it less valuable as a potential therapy for RSV bron-
chiolitis. The aim of the current study was to determine whether
post-infection treatment with the active metabolite of lefluno-
mide, A77-1726, could produce similar beneficial effects on
AFC, lung edema, and hypoxemia in a murine model of RSV
infection. Some of the results of these studies have previously
been reported in the form of abstracts (12–14).
MATERIALS AND METHODS
Preparation of Viral Inocula and Infection of Mice
Preparation of viral stocks and intranasal infection of 8- to 12-week-old
pathogen-free BALB/c mice of either sex with RSV strain A2 (106
plaque-forming units in 100 ml) were performed as previously de-
scribed (10). All mouse procedures were approved by the UAB and
OSU Institutional Animal Care and Use Committees.
Reagents
Leflunomide, A77-1726, genistein, and amiloride were reconstituted in
dimethyl sulfoxide (DMSO), aliquoted, and stored frozen. Uridine was
reconstituted in sterile normal saline. All reagents were from Sigma-
Aldrich (St. Louis, MO).
AFC Measurements
AFC was measured as previously described (10). Briefly, mice were
anesthetized with diazepam (1.75 mg/100 g, intraperitoneally; Abbott
Laboratories, Abbott Park, IL) followed 6 minutes later by ketamine
(45 mg/100 g, intraperitoneally) and were placed on a heating pad
(Braintree Scientific, Cambridge, MA). The trachea was exposed and
cannulated with a trimmed 18-gauge intravenous catheter, which was
then connected to a mouse respirator (model 687; Harvard Apparatus,
Holliston, MA). Mice were paralyzed with pancuronium bromide (0.04
mg, intraperitoneally; Gensia Pharmaceuticals, Irvine, CA) and venti-
lated with 100% O2 with a 200-ml tidal volume (8–10 ml/kg body wt) at
160 breaths/minute. Once stable anesthesia was obtained, mice were
positioned in the left decubitus position, and 300 ml of isosmolar NaCl
containing 5% fatty acid–free bovine serum albumin was instilled via
the tracheal cannula, followed by 100 ml of room air to clear dead
space. After instillation, mice were ventilated for a 30-minute period,
then the alveolar fluid was aspirated. AFC was calculated from the
ratio between the protein concentration of the instillate before
instillation and of the alveolar sample at 30 minutes.
All reagents were added to the AFC instillate from stock solutions
directly before instillation, in a minimal volume of solvent (1–10 ml/ml).
Previous studies have demonstrated that mock infection has no effect
on AFC or other measured lung parameters, and that measured de-
clines in AFC are not a consequence of instillate dilution by intra-
pulmonary edema fluid, but require replication-competent virus (10).
No sex difference in AFC rate has been found in BALB/c mice.
Topical (Intranasal) Inhibition of De Novo
Pyrimidine Synthesis
Mice were lightly anesthetized. One hundred microliters of saline,
containing 0.5 ml A77-1726 in DMSO, was administered dropwise, via
both nares, at Day 1 after RSV infection. Control animals received an
equal volume of saline 1 DMSO. Mice were placed in lateral recum-
bency, allowed to recover, and returned to their cage.
Peripheral Blood Arterial Oxygen Saturation
SpO2 was measured in conscious mice using the MouseOx system (Starr
Life Sciences Corp., Allison Park, PA), in accordance with manufac-
turer’s instructions. To ensure accurate sensor placement, SpO2 data
points were excluded from analysis if one of the four measured param-
eters (SpO2, pulse rate, pulse distension, and respiratory rate) received
an error code during measurement. Data were collected for a minimum
of 10 s (150 data points) per sample. Arterial PO2 was estimated from
SpO2 using the Ventworld interactive oxyhemoglobin dissociation curve
tool(http://www.ventworld.com/resources/oxydisso/oxydisso.html),assum-
ing a normal blood pH and arterial PCO2.
Measurement of Airway Resistance
Mice were anesthetized using the same regimen as for AFC studies.
Total lung resistance was measured in mice undergoing mechanical
ventilation at 150 breaths per minute on a computer-controlled piston
ventilator (flexiVent; Scireq Scientific Respiratory Equipment Inc.,
Montreal, PQ, Canada), with 3 cm H2O PEEP, as previously described
(15). R was recorded after performance of two TLC maneuvers to
standardize volume history and administration of normal saline by
Aeroneb nebulizer. Data were analyzed using the single compartment
model. Female mice only were used in these studies, since male mice
exhibit exaggerated AHR responses to methacholine (MCH) (16).
Other Procedures
All other procedures were performed as previously described (10, 17,
18).
Statistical Analyses
Descriptive statistics were calculated using Instat software (GraphPad,
San Diego, CA). Differences between group means were analyzed by
ANOVA, with Tukey-Kramer multiple comparison post-tests. All data
values are presented as mean 6 SEM.
RESULTS
Effect of Post-Infection Systemic Leflunomide Treatment on
RSV-Mediated Inhibition of AFC at Day 2
Previously, we had shown that, in the BALB/c mouse model,
pretreatment with the dihydro-orotate dehydrogenase inhibitor
leflunomide by oral gavage for 7 d blocked RSV-mediated inhi-
bition of AFC at Day 2 after infection (when AFC is most im-
paired) (9). However, we have found in subsequent studies that
post-infection gavage with leflunomide at Day 1 had no bene-
ficial effect on AFC at Day 2 (mean AFC rate 20.5 6 2.3% in
leflunomide-treated mice, n 5 15, versus 21.4 6 1.2% in un-
treated animals, n 5 19, 34.2 6 1.1% in uninfected animals, n 5
10). AFC rates in uninfected mice and at Day 2 in the current
study are comparable to those that we have reported previously
using this model (9, 10).
Effect of Topical Nucleotide Synthesis Inhibition on
RSV-Mediated Inhibition of AFC at Day 2
We hypothesized that the lack of effect of post-infection
leflunomide treatment at Day 1 on AFC at Day 2 was a result
of the need for its metabolism to an active form, and of poor
bioavailability in the lungs after a single dose (since 90% of the
drug remains bound to plasma proteins [11]). We therefore de-
cided to investigate the effects of intrapulmonary administra-
tion of the active metabolite of leflunomide, A77-1726, on AFC
after RSV infection. In agreement with our hypothesis, addition
of 25 mM A77-1726 to the AFC instillate resulted in complete
blockade of RSV-induced suppression of AFC at Day 2 and
returned AFC to control levels (Table 1). A77-1726 also re-
stored normal amiloride sensitivity to AFC at Day 2: amiloride
reduced AFC by 56% in the presence of A77-1726 at Day 2,
while our previous studies (10) have shown that amiloride
reduces AFC by 61% in uninfected mice and has no effect on
AFC at Day 2 in untreated, RSV-infected mice.
Dihydro-orotate dehydrogenase inhibitors such as A77-1726
also have nonspecific tyrosine kinase inhibitory activity (19).
However, the beneficial effect of A77-1726 on AFC at Day 2
was not replicated by the broad-spectrum tyrosine kinase inhi-
bitor genistein, even at a concentration of 25 mM (Table 1),
380 AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL 37 2007
which is far greater than that which has been shown previously
to be effective at tyrosine kinase blockade in a rat AFC model
(1 mM) (20). Furthermore, blockade of RSV-mediated AFC
inhibition by A77-1726 was reversed by concomitant addition of
10 mM uridine to the instillate, which allows pyrimidine syn-
thesis via a salvage pathway, indicating the A77-1726 block is
specific to the de novo pyrimidine synthesis pathway. Uridine
alone had no effect on AFC in RSV-infected mice.
Effect of Intranasal A77-1726 Treatment at Day 1 after RSV
Infection on RSV-Mediated Inhibition of AFC at Day 2
Since topical, post-infection treatment with A77-1726 appeared
effective in blocking RSV-mediated inhibition of AFC at Day 2
after infection, we wished to determine whether A77-1726
might provide prolonged therapeutic benefit. When A77-1726
(10–50 mM, but not 1 mM, in DMSO) was administered intra-
nasally at Day 1 after infection, its blocking effect on RSV-
induced inhibition of AFC persisted for at least 24 hours: AFC
remained at control levels at Day2, even in the absence of
further addition of A77-1726 to the AFC instillate (Figure 1A).
In contrast, administration of an equivalent volume of DMSO
in saline (100 ml of 5 ml/ml solution) alone intranasally at Day 1
had no beneficial effect on AFC at Day 2. However, in spite of
this ability to restore normal AFC to RSV-infected mice, intra-
nasal treatment with 10 or 50 mM A77-1726 did decrease AFC
in uninfected mice 24 hours later, by 19% and 34%, respectively
(Figure 1B). This effect is comparable to that which we ob-
served previously after treatment of uninfected mice with
leflunomide (9).
Effect of Intranasal A77-1726 Treatment at Day 1 after RSV
Infection on Lung Water Content at Day 2
Treatment of mice with 50 mM A77-1726 by intranasal instilla-
tion at Day 1 after infection restored normal lung wet:dry
weight ratios at Day 2 (Figure 2), but had no significant effect
on lung water content in mock-infected mice (mean wet:dry
weight ratio 4.54 6 0.05 in A77-1726–treated mice, versus 4.67 6
0.03 in untreated animals, n 5 8 for both groups). In contrast,
intranasal treatment with an equivalent volume of DMSO in
saline (100 ml of 5 ml/ml solution) at Day 1 had no beneficial
effect on wet:dry weight ratios at Day 2.
Effect of Intranasal A77-1726 Treatment at Day 1 after
RSV Infection on Bronchoalveolar Lavage Nucleotide
Levels at Day 2
Previously, we demonstrated that RSV infection resulted in a
doubling of bronchoalveolar lavage (BAL) UTP and ATP
levels at Day 2 (9). Intranasal treatment with 50 mM A77–
1726 at Day 1 after infection returned BAL UTP and ATP
content at Day 2 to levels comparable to those in untreated,
uninfected mice (Figures 3A and 3B). These findings are con-
sistent with the observation that de novo purine and pyrimidine
synthesis pathways are usually concordantly regulated (re-
viewed in Ref. 21). Interestingly, despite causing mild suppres-
sion of AFC in uninfected mice 24 hours later, intranasal
treatment of uninfected mice with A77-1726 had no stimulatory
effect on BAL nucleotide content. This differs from our pre-
vious finding after treatment of uninfected mice with leflunomide,
Figure 1. Effect of intranasal A77-1726 treatment at Day 1 after RSV
infection on AFC at Day 2. (A) Effect of intranasal instillation of 100 ml
saline containing DMSO vehicle (open bar), or 1 (darkly shaded bar), 10
(hatched bar), and 50 (lightly shaded bar) mM A77–1726 at d1 after RSV
infection on % AFC over 30 minutes at Day 2 (n 5 19 for untreated
mice [solid bar]; n 5 7 for DMSO; n 5 9 for 1 mM A77–1726; n 5 7 for
10 mM A77–1726; n 5 14 for 50 mM A77-1726). Dotted line indicates
mean AFC rate in untreated, uninfected mice (n 5 10). (B) Effect of
intranasal instillation of 100 ml saline containing 10 (hatched bar) or 50
(shaded bar) mM A77-1726 on % AFC over 30 minutes in uninfected
mice, 24 hours later (n 5 10 for untreated mice [solid bar]; n 5 9 for
10 mM A77-1726–treated mice; n 5 10 for 50 mM A77-1726–treated
mice). *P , 0.05, **P , 0.005, ***P , 0.0005, compared with
untreated mice.
TABLE 1. EFFECT OF ADDITION OF INHIBITORS OF DE NOVO
PYRIMIDINE SYNTHESIS TO THE ALVEOLAR FLUID CLEARANCE
INSTILLATE ON ALVEOLAR FLUID CLEARANCE AT DAY 2 AFTER
RESPIRATORY SYNCYTIAL VIRUS INFECTION
Treatment Concentration (mM) n* % AFC30†
None — 19 21.4 6 1.2
A77-1726 25 18 34.1 6 1.1‡
A77-1726 1 Amiloride 25 1 1500 6 15 6 3.2
Genistein 25 7 20.4 6 0.7
A77-1726 1 Uridine 25 1 10 13 24 6 1.8
Uridine 10 7 21.8 6 1.9
Definition of abbreviation: AFC, alveolar fluid clearance.
* Number of mice in which AFC was evaluated.
† Mean % AFC over 30 min 6 SEM.
‡ % AFC30 in uninfected mice is 34.2 6 1.1 (n 5 10) (P , 0.0005 versus
untreated AFC at Day 2).
Figure 2. Effect of intranasal
A77-1726 treatment at Day 1
after RSV infection on lung
water content at Day 2. Effect
of intranasal instillation of
100 ml saline containing 0.5
ml DMSO (open bar) or 50 mM
A77-1726 (shaded bar) at Day
1 on lung wet:dry weight
ratio at Day 2 after RSV infec-
tion (n 5 7–8 per group).
Solid bar, Day 2. Dotted line indicates mean wet:dry weight ratio in
untreated, mock-infected animals (n 5 8). ***P , 0.0005, compared
with untreated mice.
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when suppression of AFC was associated with elevated BAL
nucleotide levels (9).
Effect of Intranasal A77-1726 Treatment at Day 1 after RSV
Infection on Peripheral Blood Oxygen Saturation at Day 2
RSV had a very significant overall effect on peripheral blood
oxygen saturation (SpO2) in conscious mice over the 8-d in-
fection period (P , 0.0005 by ANOVA), and impairment of
AFC at Day 2 was temporally associated with a statistically
significant (P , 0.05, by Tukey-Kramer post-test) reduction
(1.95%) in SpO2 (Figure 4). This corresponds to a decline in
arterial PO2 from 82 to 71 mm Hg. No change in either res-
piratory rate or heart rate was detected at any time after
infection (data not shown). Treatment of mice with 50 mM
A77-1726 by intranasal instillation at Day 1 prevented the
decline in SpO2 readings seen in untreated, RSV-infected,
conscious mice at Day 2, but had no significant effect on SpO2
at later time points after infection. Mean SpO2 values in A77-
1726–treated RSV-infected mice at Day 2 were significantly
higher than in untreated animals. In contrast, intranasal treat-
ment with an equivalent volume of DMSO in saline at Day 1
had no beneficial effect on SpO2 at d2. Finally, intranasal treat-
ment of uninfected mice with 10 mM A77–1726 did not result in
hypoxemia 24 hours later (mean SpO2 96.25 6 0.3%, n 5 10),
despite causing a 19% decrease in AFC.
Effect of RSV Infection and Intranasal A77-1726 Treatment at
Day 1 on Baseline Airway Resistance
Infection with RSV resulted in a significant increase in baseline
airway resistance at Day 2, but not at other time points after
infection (Figure 5). Increased airway resistance at Day 2 was
reversed by intranasal administration of 50 mM A77-1726 at
Day 1.
Effect of Intranasal A77-1726 Treatment at Day 1 after RSV
Infection on BAL Cytokines and Chemokines
Post-infection intranasal treatment with 50 mM A77-1726 had a
very limited effect on BAL cytokine and chemokine responses
after RSV infection (Table 2). Interestingly, treatment with the
A77-1726 vehicle DMSO at Day 1 had some proinflammatory
effects (induction of BAL IL-1b and TNF-a at Day 2, and of
TNF-a at Day 4). These proinflammatory effects of the vehicle
at Day 2 were abrogated by A77-1726 itself, resulting in nor-
malization of IL-1b levels and complete suppression of TNF-a.
However, the anti-inflammatory effect of A77-1726 on TNF-a
did not persist until Day 4. Intranasal A77-1726 treatment at
Day 1 also significantly reduced BAL keratinocyte cytokine (KC)
(murine homolog of CXCL8) chemokine levels at Day 2 after
RSV infection, but not later time points. However, DMSO
treatment had a similar effect. Some limited suppression of
CCL3 (MIP-1a) was seen after A77-1726 treatment, but only at
Day 8. Neither DMSO nor A77-1726 treatment had any effect
on BAL IFN-g or CCL5 (RANTES) levels at any time point
after infection. A77-1726 treatment had no significant effect on
the minimal levels of proinflammatory cytokines and chemo-
kines detectable in BAL fluid from mock-infected mice.
Effect of Intranasal A77-1726 Treatment at Day 1 after RSV
Infection on BAL Cell Counts
Post-infection intranasal treatment of mice with 50 mM A77-
1726 also resulted in a significant reduction in BAL total cell
counts at Day 2 (Figure 6A), although numbers remained ele-
vated above those in uninfected mice. The decline in BAL
cellularity was primarily due to a drop in BAL alveolar macro-
phages—no significant changes in BAL neutrophil or lympho-
cyte counts were observed after intranasal A77-1726 treatment
(Figure 6B).
Effect of Intranasal A77-1726 Treatment at Day 1 after RSV
Infection on RSV Replication in Mouse Lungs
Treatment of mice with DMSO or 50 mM A77-1726 by intra-
nasal instillation at Day 1 had no effect on viral growth at any
time point after infection (Figure 7). Moreover, unlike with
leflunomide treatment (10), viral replication was not prolonged
to Day 8—replication of RSV was undetectable at Day 8 in
untreated, intranasal DMSO-treated, and intranasal A77-1726–
treated animals.
DISCUSSION
Bronchiolitis results in estimated hospitalization rates of 30 per
1,000 children younger than 1 year old in the United States and
Europe (22), and RSV remains its most common underlying
cause (23). There is much controversy regarding the best
approach to treatment of RSV bronchiolitis (24). b-adrenergic
agonists are frequently prescribed, primarily as bronchodilators,
but there is little conclusive evidence that they are effective
(25), and recent studies suggest that RSV may induce insensi-
tivity to their actions (26). Likewise, systemic corticosteroids
(27) and ribavirin (28) appear to provide no clinical benefit in
Figure 3. Effect of intranasal A77-1726 treatment at Day 1 after RSV
infection on BAL nucleotide levels at Day 2. (A) Bal UTP levels (n 5 10
for uninfected, untreated mice; n 5 7 for uninfected, A77-1726–
treated mice; n 5 14 for RSV-infected, untreated mice; n 5 11 for
RSV-infected, A77-1726–treated mice). (B) BAL ATP levels (n 5 11 for
uninfected, untreated mice; n 5 7 for uninfected, A77-1726–treated
mice; n 5 14 for RSV-infected, untreated mice; n 5 12 for RSV-infected,
A77-1726–treated mice). BAL nucleotide levels for untreated groups
were previously published (9), although samples for all groups were
collected contemporaneously. *P , 0.05, ***P , 0.005, compared with
uninfected, untreated mice. Solid bars, untreated mice; open bars, mice
treated with A77-1726.
Figure 4. Effect of RSV infec-
tion and intranasal A77-1726
treatment at Day 1 after RSV
infection on peripheral oxy-
gen saturation. Time course
of effect of RSV infection and
intranasal instillation of 100 ml
saline containing 0.5 ml of
DMSO (squares) or 50 mM
A77-1726 (circles) at Day 1
on SpO2 in conscious BALB/c
mice (n 5 10–20 per day).
**P , 0.005, compared with
untreated mice (triangles).
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children with bronchiolitis. Finally, trials of surfactant, immu-
noglobulins, heliox, vitamin A, interferon, and erythropoietin in
the ICU setting have been inconclusive (29). Only supportive
care (supplemental oxygen, suctioning, and parenteral fluid re-
placement) appears beneficial (4). In these circumstances, new
and effective approaches to therapy are urgently needed.
Previously, we had shown that we could prevent RSV-
mediated nucleotide release, AFC inhibition, and the physiologic
sequelae thereof, including hypoxemia, by systemic pretreat-
ment of BALB/c mice with leflunomide (an inhibitor of de novo
pyrimidine synthesis) for 7 days (9). However, we found that,
as a consequence of its poor pharmacodynamic profile (11),
leflunomide is completely ineffective in abrogating effects of
RSV on AFC when given after infection. In contrast, its active
metabolite, A77-1726, was effective as both a topical treatment
(added to the AFC instillate) and as an intranasal pretreatment
(administered at Day 1 after infection) in blocking RSV-
mediated inhibition of AFC at Day 2.
Results of our previous studies with leflunomide had sug-
gested that UTP release from the respiratory epithelium is
limited by UTP availability in cells: the pool of UTP that is
normally available for release is small, and primarily derived
from de novo pyrimidine synthesis (9). The effects of A77-1726
on AFC, when this drug is added directly to the AFC instillate
at Day 2, tend to support this contention. For RSV-mediated
inhibition of AFC to be blocked so rapidly under these
conditions, the extracellular UTP that is activating P2Y recep-
tors must be derived from continuous de novo synthesis, since
the uridine salvage pathway is not sensitive to inhibition by
A77-1726. Furthermore, this result suggests that the half-life of
extracellular UTP is very short and that maintenance of the
elevated extracellular steady-state UTP concentrations required
to inhibit AFC necessitates a constant efflux of newly synthe-
sized intracellular UTP: if the extracellular UTP that mediates
AFC inhibition has a prolonged half-life in the bronchoalveolar
space, or were derived from an intracellular pool independent
Figure 5. Effect of RSV infection and intranasal A77-1726
treatment at Day 1 after RSV infection on baseline airway
resistance. Time course of effect of RSV infection on total
lung resistance (R) in BALB/c mice undergoing mechanical
ventilation at 150 breaths per minute on a computer-
controlled flexiVent piston ventilator with 3 cm H2O PEEP
(n 5 10–20 per day). Also shown is effect of intranasal
instillation of 100 ml saline containing 50 mM A77-1726 at
Day 1 on R at Day 2. *P , 0.05, compared with uninfected
mice (solid bars). Open bars, Day 2; darkly shaded bars, Day
2 1 A77; hatched bars, Day 4; lightly shaded bars, Day 6;
cross-hatched bars, Day 8.
TABLE 2. EFFECT OF INTRANASAL TREATMENT WITH DIMETHYL SULFOXIDE OR 50 mM A77-1726 AT
DAY 1 AFTER RESPIRATORY SYNCYTIAL VIRUS INFECTION ON BRONCHOALVEOLAR LAVAGE CYTOKINE
AND CHEMOKINE LEVELS
n* IL-1b† TNF-a† IFN-g† KC† CCL5† CCL3†
Uninfected 14 29 6 10 0 0 63 6 14 36 6 19 25 6 1
Mock-infected 6 47 6 14 0 0 55 6 16 26 6 6 31 6 3
Mock, DMSO-Tx 6 40 6 13 0 0 122 6 33 11 6 11 28 6 7
Mock, A77-1726-Tx 6 27 6 5 25 6 15 0 116 6 15 20 6 3 30 6 2
Day 2 14 106 6 19 140 6 25 0 777 6 50 508 6 23 71 6 8
Day 2, DMSO-Tx 6 266 6 20‡ 366 6 48‡ 0 554 6 62‡ 531 6 12 92 6 9
Day 2, A77-1726-Tx 12 95 6 20 0‡ 0 588 6 42‡ 571 6 25 81 6 7
Day 4 6 35 6 13 0 598 6 99 181 6 25 208 6 30 81 6 13
Day 4, DMSO-Tx 6 18 6 7 110 6 9‡ 699 6 82 162 6 15 203 6 21 85 6 10
Day 4, A77-1726-Tx 6 79 6 18 105 6 30‡ 582 6 83 164 6 20 212 6 17 106 6 10
Day 6 6 61 6 13 0 398 6 83 78 6 12 117 6 6 121 6 24
Day 6, DMSO-Tx 6 101 6 24 0 300 6 72 95 6 8 76 6 18 125 6 16
Day 6, A77-1726-Tx 6 169 6 24 0 368 6 131 164 6 42 55 6 27 133 6 20
Day 8 6 33 6 5 0 270 6 16 153 6 19 114 6 19 177 6 33
Day 8, DMSO-Tx 6 32 6 9 0 330 6 42 146 6 20 108 6 9 147 6 46
Day 8, A77-1726-Tx 6 81 6 18 0 196 6 37 158 6 20 88 6 11 26 6 11‡
Definition of abbreviations: BAL, bronchoalveolar lavage; KC, keratinocyte cytokine.
* Number of mice in which BAL cytokine/chemokine levels were measured.
† Mean concentration in BAL fluid 6 SEM (pg/ml)
‡ P , 0.0005 versus untreated mice at the same time point.
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of active de novo pyrimidine synthesis (either a storage pool, or
one resulting from salvage synthesis), then there would be
sufficient UTP to mediate AFC inhibition for at least the
duration of the AFC measurement (30 min) and topical A77-
1726 would have no effect. Indeed, previous in vitro studies
have demonstrated that UTP and ATP are rapidly degraded by
ectonucleotidases at the respiratory mucosal surface (30), which
supports our contention that continuous de novo nucleotide
synthesis is necessary to maintain AFC inhibition.
We have previously shown that infection of mice with RSV
resulted in mild hypoxemia in conscious mice at Day 2, which was
reversible following pretreatment with leflunomide (9). How-
ever, because of the very rapid pulse rate of the mouse, we were
only able to measure mean O2 saturation values from arterial and
venous blood (SmO2), which therefore appear low (85%) relative
to true SpO2 values (95%) even in uninfected mice. In the current
study, we used the newly available MouseOx system, which can
accurately measure true SpO2, in addition to other physiologic
parameters, in conscious mice at a 15-Hz sampling rate. More-
over, the associated software allows accurate sensor placement,
since error codes are displayed when arterial pulse signals do not
conform to the software algorithm, so that erroneous data may
be excluded. To our knowledge, our study is the first to be
published using this system. We found that infection with RSV is
associated with a significant reduction in SpO2 at Day 2 only,
which is when AFC is most impaired (by 43% from mock-
infected values). The lack of decline in SpO2 at Day 4 suggests
that the degree of AFC impairment at this time point (21%) is
insufficient to result in detectable hypoxemia. Indeed, we were
similarly unable to detect hypoxemia in uninfected mice 24 hours
after intranasal treatment with 10 mM A77-1726, which causes a
comparable decline in AFC (19%).
The time course of effect of RSV on SpO2 described herein
was almost identical to that which we reported previously for
SmO2 (9), and results of the two techniques were very strongly
correlated (P , 0.0005), confirming the validity of our earlier
findings. Interestingly, van Schaik and coworkers (31) previ-
ously reported an early peak in respiratory rate at Day 1 to Day
2 after RSV infection, measured by whole-body plethysmog-
raphy, although they also found a second period of tachypnea at
Day 6, which they associated with the onset of the specific
immune response to infection. We found no hypoxemia at Day
6 and no tachypnea at any time point after infection, although
this latter finding may be a consequence of the greater animal
handling required for SpO2 measurement versus plethysmogra-
phy, which may have artificially altered respiratory rates. Never-
theless, our findings are supported by the observation of
Welliver and colleagues (32) that in human patients, severity
of hypoxemia during RSV infection is poorly correlated to T
cell cytokine levels.
Although the observed decrease in mean SpO2 at Day 2 in
RSV-infected mice appears small (2%), this nevertheless cor-
responds to a decline in arterial PO2 of 10 mm Hg. Moreover, an
SpO2 of 94%, which is greater than the mean value observed in
our study at Day 2 (93.5%), has also been suggested as a lower
acceptable limit for bronchiolitis outpatient therapy (33), and
has been defined by some authors as indicative of hypoxemia
(34). In one recent study, an SpO2 below 95% was found to be
highly predictive of admission to the pediatric ICU in full-term
infants with bronchiolitis that lack other underlying illnesses
(35). Most importantly, the limited hypoxemia observed in con-
scious mice at Day 2 could be prevented by intranasal A77-1726
treatment at Day 1, as we had previously shown for leflunomide
pretreatment (9). This finding further supports our hypothesis
that hypoxemia during RSV bronchiolitis may result from
nucleotide-mediated impairment of AFC. Furthermore, intra-
nasal A77-1726 treatment had no detrimental effect on SpO2 at
later time points after infection.
Unlike systemic leflunomide treatment (9), intranasal A77-
1726 treatment at Day 1 had only a limited suppressive effect on
the intrapulmonary proinflammatory cytokine/chemokine re-
sponse at Day 2, since it induced significant reductions only in
BAL KC and TNF-a levels. However, a comparable suppressive
effect on BAL KC levels was also noted after intranasal DMSO
treatment at Day 1, suggesting that the reduction in BAL KC
levels at Day 2 after intranasal A77 treatment at Day 1 is an
effect of the vehicle rather than the drug itself. DMSO has
previously been shown to suppress IL-8 production by RSV-
infected A549 cells, as a consequence of its antioxidant proper-
ties (36). While the suppressive effect of A77 treatment on BAL
TNF-a levels was not replicated by DMSO alone, our previous
studies demonstrated that leflunomide’s effect on RSV-induced
AFC inhibition was reversed by uridine, but its effect on BAL
TNF-a levels was not (9). Taken together, these findings suggest
that the beneficial effect of A77-1726 treatment on AFC in RSV
Figure 6. Effect of intranasal A77-1726 treatment at Day 1 after RSV
infection on BAL cell counts. (A) Total counts. (B) Alveolar macrophage
counts. (C ) Lymphocyte counts. (D) Neutrophil counts (n 5 6–8 per
group). **P , 0.005, ***P , 0.0005, compared with uninfected mice.
*P , 0.05, compared with untreated, RSV-infected mice at Day 2. Solid
bars, untreated; open bars, DMSO; shaded bars, A77.
Figure 7. Effect of intranasal
A77-1726 treatment at Day 1
after RSV infection on RSV rep-
lication in mouse lungs at Day
2. Effect of intranasal instilla-
tion of 100 ml saline containing
0.5 ml DMSO (open bars) or 50
mM A77-1726 (shaded bars) in
0.5 ml DMSO at Day 1 on lung
homogenate viral titers at Days
2 to 8 after RSV infection (n 5
6–12 per group). ND: none
detected. Solid bars, untreated.
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infection is not a consequence of its immunosuppressive effects,
but instead results from its inhibitory effect on de novo pyrim-
idine synthesis.
Intranasal A77-1726 treatment at Day 1 also blocks the
increase in BAL alveolar macrophage counts in response to
infection at Day 2, although it has no effect on BAL lymphocyte
or neutrophil responses to RSV. Previously, we had found that
continuation of leflunomide treatment to Day 8 after infection
resulted in impaired leukocyte recruitment to the airspaces and
histopathologic evidence of trapping of leukocytes around ma-
jor blood vessels (9). These data suggest that either nucleotides
themselves, or the cytokines and chemokines that they induce,
may be important for recruitment of alveolar macrophages to
the lung in the early phase of RSV infection. Interestingly, nu-
cleotides have been shown to promote monocyte chemotaxis
(37), and our findings may reflect this role. Taken together, the
alteration in pulmonary humoral and cellular responses to RSV
infection observed after inhibition of de novo pyrimidine syn-
thesis suggest that nucleotides may play a significant role in the
initiation of the immune response to RSV infection (although
this alteration may be partially attributed to the tyrosine kinase
inhibitory activity of these drugs [19]). Nevertheless, irrespec-
tive of the underlying mechanism, the immunosuppressive
activity of A77-1726 may be an additional beneficial property
of this drug, since an elevated nasal lavage or lung level of
CXCL8, which intranasal A77-1726 reduces, may be an indica-
tor of increased disease severity in children with RSV (38, 39).
Our previous studies had demonstrated that the inhibitory
effect of RSV on AFC requires active viral replication (10), and
the beneficial effect of A77-1726 on AFC at Day 2 might
therefore simply result from an antiviral activity. However,
neither intranasal A77-1726 treatment nor intranasal DMSO
treatment at Day 1 had any effect on viral replication kinetics in
mouse lungs. The beneficial effect of A77-1726 on basal and
amiloride-sensitive AFC at Day 2 is not therefore simply a con-
sequence of inhibition of viral replication, but is rather a specific
modulatory effect on epithelial cell function. Moreover, unlike
leflunomide therapy, intranasal A77-1726 treatment at Day 1
does not prolong viral replication to Day 8. This finding suggests
that, despite any immunosuppressive effects, this treatment
does not impede normal antiviral clearance mechanisms.
In conclusion, our studies indicate that post-infection intra-
nasal therapy with an inhibitor of de novo pyrimidine synthesis
can have a prolonged beneficial effect on the pathophysiologic
consequences of RSV infection in the BALB/c mouse model—
intranasal A77–1726 treatment at Day 1 after RSV infection is
able to restore normal AFC and alleviate lung edema 24 hours
later, thereby helping to counter the development of hypoxe-
mia, without impairing clearance of RSV from the lung in the
long term. Post-infection intranasal or aerosolized therapy with
pyrimidine synthesis inhibitors may therefore have the potential
to provide symptomatic relief from the pathophysiologic seque-
lae of impaired AFC in children with severe RSV disease. To
our knowledge, this is the first report of an effective post-
infection therapy for hypoxemia in RSV bronchiolitis in the
murine model, other than supplemental oxygen.
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